Today in the @TheLancet, we UK geneticists argue: "Population screening requires robust evidence—genomics is no exception"
@annekeluc, @HelenVFirth, @GeneticBill, @carolinefwright, @mgtmccartney, @wilkie_lab, @RobinLachmann,@group_tomlinson,@lucymedgen authors.elsevier.com/a/1iD4W…
Dec 7, 2023 · 8:26 AM UTC
10
69
165
47,607
Proponents of PRS seem to be those with companies marketing PRS or large grants investigating/cataloging PRS.
Sceptics of PRS seem to be those with experience in clinical-public health genomics with no skin in the game.
Not perfect segregation, but I bet chi-squared significant.
1
3
10
1,975
I here am clumsily defining <<PRS>> to mean <<PRS for population-level stratification for allocation of screening/preventative drugs>>. Which is primary use-case for most, especially to industry.
Conversely, PRS for risk-modification in patient groups already ascertained .. 1/2
1
1
358
as being of prior elevated risk (eg BRCA/ATM/CHEK2 path var, or strong family history) is likely to be very useful in best directing interventions, as exemplified by excellent CanRisk/BOADICEA tool widely used in cancer genetics (from @antonis02 at @CCGE_Cambridge) 2/2
3
378
